期刊文献+

15-脱氧前列腺素J_2对非酒精性脂肪肝大鼠影响的研究 被引量:1

Effects of 15-Deoxidizing Prostaglandin J_2 to rats with nonalcoholic fatty liver disease
下载PDF
导出
摘要 目的研究15-脱氧前列腺素J2(15d-PGJ2)对非酒精性脂肪肝(NAFLD)大鼠的治疗作用。方法高脂饲料喂养Wistar大鼠12周制备NAFLD大鼠模型,再将其随机分为HI组(15d-PGJ2高剂量干预组)、LI组(15d-PGJ2低剂量干预组)、MC组(模型对照组);将普通饲料喂养大鼠作为NC组(正常对照组)。干预2周后检测肝组织匀浆中三酰甘油(TG)、总胆固醇(TC),血清丙氨酸转氨酶(ALT)、TG、TC及血糖(GLU)的含量,观察各组大鼠的肝组织病理学变化。结果高脂饮食可引起大鼠肝脏脂肪变性。HI组所有检测指标及LI组肝内TC水平均高于NC组;LI组和NC组所有检测指标及HI组ALT、TC、TG水平均低于MC组;HI组ALT、TG、GLU水平均高于LI组,差异有统计学意义(P<0.05)。HI组、LI组肝组织脂肪变性程度较MC组改善更明显。结论 15d-PGJ2可有效改善NAFLD大鼠的肝脏病变。 Objective To study the therapeutic action of 15-Deoxy-△12,14-prostaglandin J2(15d-PGJ2) on nonalcoholic fatty liver disease(NAFLD)in rats.Methods Wistar rats were fed with high-lipid diet for 12 weeks to induce nonalcoholic fatty liver model.Then randomly divided into 15d-PGJ2 higher dose intervention group(HI),15d-PGJ2 lower dose intervention group(LI),and model control group(MC).Ordinary diet fed rats were regarded as group NC(normal controls).After two weeks intervention,observe the liver tissue pathology change.The triglyceride(TG),total cholesterol(TC)of liver and alanine aminotransferase(ALT),TG,TC,glucose(GLU) of blood were measured by biochemisty methods.Results All indexes of intrahepatic of group HI and TC of group LI were higher than that in the NC group;all indexes of LI group and NC group and ALT,TC,TG in HI group lower than MC group;ALT,TG,GLU in group HI were higher than those in LI group,the difference was statistically significant(P0.05).Liver steatosis degree was improved more obviously In group HI and group LI,when compared with MC group.Conclusion The 15d-PGJ2 can effectively improved the liver lesions of the rats with NAFLD.
出处 《临床合理用药杂志》 2012年第11期6-8,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 15-脱氧前列腺素J2 过氧化物酶体激活受体 非酒精性脂肪肝 大鼠 15-Deoxy-△12 14-prostaglandin J2 Peroxisome proliferator-activated receptor Nonalcoholic fatty liver disease Rats
  • 相关文献

参考文献10

  • 1Guo L,Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance[J].Pharmacology and Therapeutics,2006,(01):145-173.
  • 2刘庆彤,师水生.过氧化物酶体增殖物激活受体γ及其配体与肝纤维化研究进展[J].国际消化病杂志,2007,27(2):137-139. 被引量:3
  • 3顾小红,张云东,冯爱娟.高脂饮食对大鼠非酒精性脂肪肝中解偶联蛋白2的诱导作用(英文)[J].中国临床康复,2006,10(32):169-171. 被引量:6
  • 4Fattly Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].实用肝脏病杂志,2007,10(1):1-3. 被引量:144
  • 5病毒性肝炎防治方案[J].中华内科杂志,2001,40(1):62-68. 被引量:414
  • 6Duez H,Lefebvre B,Poulain P. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2005,(03):585-591.
  • 7Mayerson AB,Hundal RS,Dufour S. The effects of rosiglitazone on insulin sensitivity,lipolysis,and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes[J].Diabetes,2002,(03):797-802.doi:10.2337/diabetes.51.3.797.
  • 8Kubota N,Terauchi Y,Kubota T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways[J].Journal of Biological Chemistry,2006,(13):8748-8755.
  • 9Abdelrahman M,Sivarajah A,Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury,inflammation and shock[J].Cardiovascular Research,2005,(04):772-781.
  • 10Hammarstedt A,Andersson CX,Rotter Sopasakis V. The effect of PPARgamma ligands on the adipose tissue in insulin resistance[J].Prostaglandins Leukotrienes and Essential Fatty Acids,2005,(01):65-75.

二级参考文献33

  • 1梁坚,王婉梅,揭育丽,梁伟娟.脂肪肝患者血清瘦素与胰岛素抵抗的关系[J].中国临床康复,2004,8(27):5847-5849. 被引量:8
  • 2胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 3LOK AS,MCMAHON BJ.Practice Guidelines Commlittee,American Association for the Study of Liver Diseases(AASLD).Chronic hepatitis B:update of recommendations[J].Hepatology,2004,39:857-861.
  • 4FARRELL GC,GEORGE J,PAULINE MH,et al.eds.Fatty liver disease:NASH and related disorders[M].Oxford:Blackwell Publishing,2005.1-22,159-207.
  • 5American Gastroenterological Association.American Gastroenterological Association Medical Position statement:nonalcoholiic fatty liver disease[J].Gastroenterology,2002,123:1702-1704
  • 6SANYAL AJ.AGA technicai review on nonalcoholic fatty liver disease[J].Gastroenterology,2002,123:1705-1725.
  • 7RAMESH S,SANYAL AJ.Evaluation and management of nonalcoholic steatohepatitis[J].J Hepatol,2005,42:S2-S12.
  • 8ECKEL RH,GRUNDY SM,ZIMMET PZ.The metabolic syndrome[J].Lancet,2005,365:1415-1428.
  • 9GRAIF M,YANUKA M,BARAZ M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease[J].Invest Radiol,2000,35:319-324.
  • 10ATTASEVEN H,YILDRIM MH,YALNIZ M,et al,Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis[J].J Hepatol,2003,38(Suppl 2):A4177.

共引文献563

同被引文献34

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部